Operator

Welcome to Medicure's earnings conference call for the quarter ended March 31, 2026. My name is Holly, and I will be your operator for today's call. [Operator Instructions] Before we proceed, I would like to remind everyone that this presentation contains forward-looking statements relating to future results, events and expectations which are made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties and which could cause the company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, those described in the company's most recent annual information form and Form 20-F.

[Operator Instructions] Please note that this conference call is being recorded, and today's date is May 25, 2026.

I would now like to turn the conference call over to Dr. Albert Friesen, Chief Executive Officer of Medicure Inc. Please go ahead, Dr. Friesen.

Albert Friesen
Founder, CEO, President & Chairman of the Board

Thank you, Holly, and good morning to all on the call. We appreciate your interest and participation in today's call. Joining me on the Q1 2026 conference call is Haaris Uddin, Medicure's Chief Financial Officer.

Net revenue for the quarter was $7.9 million compared to $5.5 million for the quarter ending March 31, 2025. The company recorded a net loss for the quarter of $406,000 or $0.04 per share compared to a net loss of $694,000 or $0.07 a share on the March 31, 2025 quarter. The net loss is due to noncash expenses, including $644,000 of amortization on the assets related to the purchase of ZYPITAMAG and the Pharmacy Business, and